Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Bayer pharma chief sees no big acquisitions in near future January 14, 2025 Leaders Bayern Munich should have scored several more goals in their 1-0 Bundesliga win at Borussia Moenchengladbach on ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Bayer pleaded with Missouri lawmakers Thursday to pass legislation critics say would shield the company from lawsuits claiming its glyphosate-based herbicide Roundup causes cancer. Representatives for ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...

Bayer has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.